• The biotechnological company takes part in the PROVACIN consortium, joined by partners Piensos Jimenez –leaders of the project- and Iberico Comercializacion (IBERCOM), with the main goal of reducing the use of antibiotics in white and iberian pigs
  • The PROVACIN project acts on the whole value chain of livestock industry, by applying different innovative solutions. It is co-founded by the Centre for Industrial and Technological Development (CDTI; Government of Spain) in the framework of the FEDER-Innterconecta 2016 Program. Bionaturis has been granted 267,360.00 Euros for the execution of the project.
  • Producers worldwide are looking for alternatives to make the use of antibiotics in animal industry sustainable, reducing practices that might lead to the rise of antimicrobial resistance while keeping or even improving quality of the final products.

 

Jerez de la Frontera, December 14, 2016.  Bionaturis continues its bet on providing solutions highly demanded by the Animal Health industry. The company has just announced its participation in the industrial consortium PROVACIN whose main goal is the design of new strategies for swine vaccination and breeding, aimed for making changes in the production of both white and Iberian pigs leading to a substantial reduction in the use of antibiotics as either preventive or therapeutic medication.

PROVACIN’s proposition is a coordinated approach acting on different aspects of animal farming, combining strategies of biosafety, prevention, feeding and handling. The project comprises innovation in feed additives, immunostimulants, and veterinary medicines. The project also assays safety and efficacy of new vaccines against common diseases in swine, immunomodulatory peptides, probiotics and natural ingredients.

Bionaturis CSO Dr. Juan José Infante explained: “PROVACIN gathers together all agents creating value in the industry, from the laboratory to the final consumer, under one common task. The aim is to adapt the production systems of white and Iberian pigs to the coming post-antibiotic era by considering two perspectives. On one hand, the perspective of science, which is showing us that antibiotic resistance is a worldwide problem whose solution requires a cross-sectorial approach. On the other hand, a social and economical perspective, since implementation of the strategies envisioned in the PROVACIN project to swine production could impact consumers by improving the quality of the final product and producers by improving production yields. Meeting the milestones set for the PROVACIN project can lead to creation of an international pole of excellence in sustainable swine farming, reducing the use of antibiotics to the minimum”. Dr. Infante also commented that “it is worth to highlight the social and environmental commitment of important producers like PROVACIN’s partners Piensos Jimenez and Ibercom, and their bet on innovation applied to all aspects of production”.

In the consortium established for development of the PROVACIN Project (‘Vaccination Programmes based on the Chain of Infection for Reducing the Use of Antibiotics in Swine’) since 2016 to 2018, Bionaturis has been joined by the companies Piensos Jimenez SL –consortium’s leader- and Iberico Comercializacion (IBERCOM), two of the major references in livestock production in Spain. Research Centers of the University of Murcia, the University of Cordoba, and “Visavet” Health Surveillance Centre –of the Complutense University of Madrid- are also collaborating in the project. The incentive has been granted by the Centre for Industrial and Technological Development (CDTI; Government of Spain) in the framework of the 2016 FEDER-Innterconecta Program and it has been co-founded by the Ministry of Economy, Industry and Competitiveness within the 2013-2016 National Plan of Scientific, Technical and Innovation Research; and by the European Union through the European Regional Development Fund (ERDF). Bionaturis has been granted a total amount of 267,360.00 Euros.

 

Antibiotic resistances, a global fight

According to the World Health Organization (WHO), resistance to antibiotics and antimicrobials has become one of the most serious threats for global health, food safety, and development.

To tackle this phenomenon requires coordinated approaches within the ‘One Health’ perspective, which takes Human, Animal, and Environmental Health together under the same umbrella. The WHO and other prestigious international institutions recommend implementation of new practices for reducing the use of antibiotics in animal production, including livestock, poultry, and aquaculture, since today’s general standards of use are considered one of the causes of the emergence and spread of antibiotic-resistant pathogens.

About Bionaturis Group

Bionaturis Group offers “premium” solutions for human and animal health; it comprises currently four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) located in six different places around the world. Bionaturis is listed on the Spanish stock exchange for SMEs (trading code BNT).

 

About Piensos Jimenez

An animal production company integrated in the business group Juan Jimenez Garcia SAU, Piensos Jimenez was founded 20 years ago and it is mainly dedicated to swine production, including white and Iberian pigs. It is located in Andalusia, with the main activity exerted in Jaen and spreading its activity to the provinces of Cordoba, Granada, Malaga and Seville.

 

About IBERCOM

Iberico Comercialización S.C.L is a national cooperative, founded in February 1999. Currently, the company has got more than 100 partners and it has been recognized by the Ministry of Agriculture of Spain as an Association of Iberian Swine Producers. Since its establishment, the company has grown considerably in volume of swine commercialization, turning into one of the most valued company in its sector.

 

 

Disclaimer

The Market and investors are informed that the Company’s developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Bionaturis’ ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Bionaturis’ patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 Currently, there are no guarantees that the development product will receive the necessary regulatory approvals or that they will prove to be commercially successful.

 

To download the press release, please click here

 www.bionaturisgroup.com

 

Para más información:                                                            

 Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047

press@bionaturis.com